Drug intelligence / Profile preview

CG-1999

Development stage: Preclinical
Lead developer: CureGene
Modality: Small Molecules

Overview

CG-1999 is a first-in-class small molecule immunomodulator developed by Shanghai CureGene Pharmaceutical Co., Ltd. It is designed to achieve a functional cure for chronic Hepatitis B (CHB) by restoring host immune responsiveness. The molecule specifically activates both the innate and adaptive immune systems to boost HBV-specific T-cell populations, enhance antigen presentation, and promote the development of durable immune memory. As of 2025, CG-1999 is in preclinical development, with research findings presented at the American Association for the Study of Liver Diseases (AASLD) meeting. The drug uniquely activates specific immune pathways to modulate the host immune system, demonstrating potential to suppress and eliminate chronic hepatitis B virus (HBV) infection.

Beyond the preview

Go deeper on CG-1999.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CG-1999.

Explore the full profile